IP Library Granted Patent US 7,655,630
Granted Patent B2
US 7,655,630 · App. 12/201,760 · Granted Feb 2, 2010

Abuse-resistant amphetamine prodrugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,655,630
App. No.
12/201,760
Granted
Feb 2, 2010
Kind
B2
Abstract

The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Claims (4)

1. The compound, L-lysine-d-amphetamine dimesylate.

2. A compound as defined in claim 1 , having a water content of about 0% to about 5% by Karl Fischer analysis.

3. A compound as defined in claim 1 , having a water content of about 0.1% to about 3% by Karl Fischer analysis.

4. A compound as defined in claim 1 , having a water content of about 0.25% to about 2% by Karl Fischer analysis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2020
From: SHIRE LLC
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 054626/0595 →